This is a review of the development of bumped-kinase inhibitors (BKIs) for the therapy of One Health parasitic apicomplexan diseases. Many apicomplexan infections are shared between humans and livestock, such as cryptosporidiosis and toxoplasmosis, as well as livestock only diseases such as neosporosis. We have demonstrated proof-of-concept for BKI therapy in livestock models of cryptosporidiosis (newborn calves infected with Cryptosporidium parvum), toxoplasmosis (pregnant sheep infected with Toxoplasma gondii), and neosporosis (pregnant sheep infected with Neospora caninum). We discuss the potential uses of BKIs for the treatment of diseases caused by apicomplexan parasites in animals and humans, and the improvements that need to be made to further develop BKIs.

本文综述了用于治疗 One Health 寄生性顶端复门疾病的碰撞激酶抑制剂 (BKI) 的开发。许多顶复门感染是人类和牲畜之间共有的，例如隐孢子虫病和弓形虫病，以及仅牲畜感染的疾病，例如新孢子虫病。我们已经在隐孢子虫病（感染小隐孢子虫的新生牛犊）、弓形体病（感染刚地弓形虫的怀孕羊）和新孢子虫病（感染犬新孢子虫的怀孕羊）的家畜模型中展示了 BKI 治疗的概念验证。我们讨论了 BKI 在治疗动物和人类中由顶复门寄生虫引起的疾病的潜在用途，以及进一步开发 BKI 需要做出的改进。